Creating a New Paradigm
with Shelf-Stable, Allogeneic Cellular Therapies
Cellphire Therapeutics has developed a first-in-class technology to stabilize and store human cells for years, and then restore them to functionality. Our technology platform enables development of novel cellular therapies to address a range of unmet medical needs. Our ability to blend cells from multiple donors and to reduce pathogens allows us to provide a consistent, safe product at commercial scale.
Cellphire has two investigational products in Phase 2 clinical trials, including Thrombosomes®, a stabilized platelet-derived biologic, and Cryopreserved Platelets (CPP).